AMERICAN COLLEGE OF SURGEONS ONCOLOGY TRIALS GROUP

美国外科医生学院肿瘤学试验组

• 批准号: 2896232
• 负责人: SAMUEL A WELLS
• 金额: $ 286.55万
• 依托单位: AMERICAN COLLEGE OF SURGEONS
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-05-15 至 2000-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2896232
• 关键词: biomarker; breast neoplasms; cancer prevention; cancer risk; clinical research; clinical trials; combination cancer therapy; cooperative study; cyclosporines; esophagus neoplasm; health care cost /financing; human subject; human therapy evaluation; intestine neoplasm; lung neoplasms; medical education; melanoma; melphalan; metastasis; multidrug resistance; neoplasm /cancer chemotherapy; neoplasm /cancer classification /staging; neoplasm /cancer diagnosis; neoplasm /cancer genetics; neoplasm /cancer immunotherapy; neoplasm /cancer palliative treatment; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; pediatric neoplasm /cancer; positron emission tomography; postoperative state; quality of life; retinoblastoma; statistics /biometry; tumor necrosis factor alpha

The American College of Surgeons (ACS) has established the American College of Surgeons Oncology Group (ACSOG) to conduct multicenter cooperative group trials designed to evaluate the role of surgical procedures in the treatment of patients with malignant solid tumors. The existence of a surgical clinical trial group is important to the oncological community because of the primary role of surgery in the treatment of the cancer patient. The trials will also evaluate the utility of selected new operations, technology, and instrumentation as they are introduced into clinical practice. Furthermore, the ACSOG will perform trials that are based on new basic science discoveries; specifically (a) the evaluation of new molecular markers in the diagnosis and treatment of the cancer patient and (b) the place of interventional therapy in patients demonstrated to have a genetic predisposition for cancer. Through its substantial education and communication programs the ACS will place great emphasis on the education of surgeons in clinical trial methodology and in the importance of their participation in the ACSOG clinical trials programs. The ACS is the largest organization of surgeons in the world with broad geographic membership distribution, including general surgeons and speciality surgeons in both academic medical centers and the private practice community. Furthermore, the Commission on Cancer (COC), of the ACS through the Approvals, Education, Cancer Liaison and National Cancer Database Programs has a large number of active professional staff and volunteers that serve and interact with the Cancer Programs and the practicing surgeons in the 1500 approved hospitals throughout the United States of America and Canada. The ACSOG is committed to performing clinical trials of patients with the most commonly occurring malignant solid tumors. This is evidenced b the concentration of the initial trials on patients with breast cancer, lung cancer and colorectal cancer. The performance of these trials will require a broad base of practicing surgeons in North America and this group of participants is well represented within the membership of the ACS.

美国外科医生学会（ACS）建立了美国 外科医生学院肿瘤组（ACSOG）进行多中心 旨在评估外科手术的作用的合作组试验 在恶性实体瘤患者的治疗过程中。 手术临床试验组的存在对于 由于手术在肿瘤治疗中的主要作用， 治疗癌症患者。 试验还将评估 选定的新操作、技术和仪器的实用性， 它们被引入临床实践。 此外，ACSOG将 进行基于新的基础科学发现的试验; 具体地说，（a）评价新的分子标记物， 癌症患者的诊断和治疗，以及（B） 介入治疗的患者被证明有遗传 易患癌症 通过其丰富的教育和 通信计划，ACS将非常重视 对外科医生进行临床试验方法学和 他们参与ACSOG临床试验计划的重要性。 ACS是世界上最大的外科医生组织， 地理成员分布，包括普通外科医生和 学术医疗中心和私人医疗中心的专业外科医生 实践社区。 此外，联合国癌症委员会（COC） ACS通过批准，教育，癌症联络和国家癌症 数据库程序拥有大量活跃的专业人员， 志愿者服务，并与癌症项目和 在全美1500家经批准的医院执业的外科医生 美国和加拿大。 ACSOG致力于对以下患者进行临床试验： 最常见的恶性实体瘤。 证明了这一点 B乳腺癌患者的初始试验浓度 癌症、肺癌和结肠直肠癌。 履行这些 试验将需要北美广泛的执业外科医生基础 这部分参与者在会员中有很好的代表性， 的ACS。